» Articles » PMID: 35681127

Meta-analysis of Diagnostic Cell-free Circulating MicroRNAs for Breast Cancer Detection

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Jun 10
PMID 35681127
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Breast cancer (BC) is the most frequently diagnosed cancer among women. Numerous studies explored cell-free circulating microRNAs as diagnostic biomarkers of BC. As inconsistent and rarely intersecting microRNA panels have been reported thus far, we aim to evaluate the overall diagnostic performance as well as the sources of heterogeneity between studies.

Methods: Based on the search of three online search engines performed up to March 21 2022, 56 eligible publications that investigated diagnostic circulating microRNAs by utilizing Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) were obtained. Primary studies' potential for bias was evaluated with the revised tool for the quality assessment of diagnostic accuracy studies (QUADAS-2). A bivariate generalized linear mixed-effects model was applied to obtain pooled sensitivity and specificity. A novel methodology was utilized in which the sample and study models' characteristics were analysed to determine the potential preference of studies for sensitivity or specificity.

Results: Pooled sensitivity and specificity of 0.85 [0.81-0.88] and 0.83 [0.79-0.87] were obtained, respectively. Subgroup analysis showed a significantly better performance of multiple (sensitivity: 0.90 [0.86-0.93]; specificity: 0.86 [0.80-0.90]) vs single (sensitivity: 0.82 [0.77-0.86], specificity: 0.83 [0.78-0.87]) microRNA panels and a comparable pooled diagnostic performance between studies using serum (sensitivity: 0.87 [0.81-0.91]; specificity: 0.83 [0.78-0.87]) and plasma (sensitivity: 0.83 [0.77-0.87]; specificity: 0.85 [0.78-0.91]) as specimen type. In addition, based on bivariate and univariate analyses, miRNA(s) based on endogenous normalizers tend to have a higher diagnostic performance than miRNA(s) based on exogenous ones. Moreover, a slight tendency of studies to prefer specificity over sensitivity was observed.

Conclusions: In this study the diagnostic ability of circulating microRNAs to diagnose BC was reaffirmed. Nonetheless, some subgroup analyses showed between-study heterogeneity. Finally, lack of standardization and of result reproducibility remain the biggest issues regarding the diagnostic application of circulating cell-free microRNAs.

Citing Articles

Confirmation of previously identified plasma microRNA ratios for breast cancer detection in a nested case-control study within a screening setting.

Sehovic E, Gregnanin I, Mello-Grand M, Ostano P, Vergini V, Ortale A Clin Transl Med. 2024; 14(11):e70068.

PMID: 39548535 PMC: 11567874. DOI: 10.1002/ctm2.70068.


Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort.

Hu Z, Lai C, Liu H, Man J, Chen K, Ouyang Q Breast Cancer. 2024; 31(6):1046-1058.

PMID: 39028497 DOI: 10.1007/s12282-024-01619-w.


Circulating micrornas as potential diagnostic biomarkers for cervical intraepithelial neoplasia and cervical cancer: a systematic review and meta-analysis.

Li Y, Zhu L, Zhu C, Chen Y, Yu H, Zhu H Discov Oncol. 2024; 15(1):189.

PMID: 38801504 PMC: 11130102. DOI: 10.1007/s12672-024-01028-7.


Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.

Abdul Manap A, Wisham A, Wong F, Ahmad Najmi H, Ng Z, Diba R Front Cell Dev Biol. 2024; 12:1390704.

PMID: 38726321 PMC: 11079208. DOI: 10.3389/fcell.2024.1390704.


Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles.

Padroni L, De Marco L, Fiano V, Milani L, Marmiroli G, Giraudo M Int J Mol Sci. 2023; 24(20).

PMID: 37894794 PMC: 10607026. DOI: 10.3390/ijms242015114.


References
1.
Matamala N, Vargas M, Gonzalez-Campora R, Minambres R, Arias J, Menendez P . Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015; 61(8):1098-106. DOI: 10.1373/clinchem.2015.238691. View

2.
Kirschner M, Kao S, James Edelman J, Armstrong N, Vallely M, van Zandwijk N . Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011; 6(9):e24145. PMC: 3164711. DOI: 10.1371/journal.pone.0024145. View

3.
Pena-Cano M, Saucedo R, Morales-Avila E, Valencia J, Zavala-Moha J, Lopez A . Deregulated microRNAs and Adiponectin in Postmenopausal Women with Breast Cancer. Gynecol Obstet Invest. 2019; 84(4):369-377. DOI: 10.1159/000496340. View

4.
Li M, Zou X, Xia T, Wang T, Liu P, Zhou X . A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med. 2019; 8(16):7006-7017. PMC: 6853814. DOI: 10.1002/cam4.2572. View

5.
Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V . Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era. ESMO Open. 2021; 6(2):100055. PMC: 7878116. DOI: 10.1016/j.esmoop.2021.100055. View